Brea Lipe

2.7k total citations
76 papers, 901 citations indexed

About

Brea Lipe is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Brea Lipe has authored 76 papers receiving a total of 901 indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 29 papers in Oncology and 26 papers in Molecular Biology. Recurrent topics in Brea Lipe's work include Multiple Myeloma Research and Treatments (51 papers), Protein Degradation and Inhibitors (18 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Brea Lipe is often cited by papers focused on Multiple Myeloma Research and Treatments (51 papers), Protein Degradation and Inhibitors (18 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Brea Lipe collaborates with scholars based in United States, Canada and Spain. Brea Lipe's co-authors include Deborah L. Ornstein, Andrew J. Portuguese, William B. Coleman, William B. Kinlaw, Luika Timmerman, Wendy A. Wells, Peter M. Morganelli, Evelien Rysman, Jason R. Pettus and Burton Eisenberg and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Brea Lipe

70 papers receiving 887 citations

Peers

Countries citing papers authored by Brea Lipe

Since Specialization

Citations

This map shows the geographic impact of Brea Lipe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brea Lipe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brea Lipe more than expected).

Fields of papers citing papers by Brea Lipe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brea Lipe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brea Lipe. The network helps show where Brea Lipe may publish in the future.

Co-authorship network of co-authors of Brea Lipe

This figure shows the co-authorship network connecting the top 25 collaborators of Brea Lipe. A scholar is included among the top collaborators of Brea Lipe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brea Lipe. Brea Lipe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: Final Analysis of the Multicenter Phase II Randomized Clinical Trial 2024 ·Blood ·Leyla Shune, (unknown), Gerhard Hildebrandt, (unknown), Howard N. Langstein, (unknown), (unknown), Andrea Baran, Jane L. Liesveld, Neil Blumberg, Brea Lipe, Andrew G. Evans, Derick R. Peterson, Omar S. Aljitawi	0
2	Personalized Treatment of Multiple Myeloma in Frail Patients 2024 ·Current Oncology Reports ·(unknown), Nadine Abdallah, Brea Lipe	2
3	P-066 Prophylactic Interventions for Oral Toxicities With the GPRC5D×CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN) 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Rakesh Popat, Alexa M. G. A. Laheij, Niels W.C.J. van de Donk, Richard L. Doty, (unknown), Brea Lipe, Leo Rasche, Ajai Chari, (unknown), (unknown), Deeksha Vishwamitra, (unknown), (unknown), (unknown), (unknown), (unknown), Kathleen Gray, (unknown), Larysa Sanchez	1
4	OA-55 Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Anna Sureda, (unknown), Albert Oriol, Mercedes Gironella, Faiz Anwer, (unknown), Brea Lipe, Paula Rodríguez‐Otero, Michael Amatangelo, Kexin Jin, (unknown), (unknown), (unknown), Paulo Maciag, Sagar Lonial	1
5	Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) 2024 ·Blood ·Muhamed Baljević, Nizar J. Bahlis, Rami Kotb, Gary J. Schiller, Brea Lipe, Sumit Madan, Heather J. Sutherland, Suzanne Lentzsch, Natalie S. Callander, Noa Biran, Dane R. Van Domelen, Tomer M. Mark, Darrell White	1
6	Denosumab for smoldering multiple myeloma: Rates of osteoporosis and change in lowest T-score after 12 months of treatment. 2023 ·Journal of Clinical Oncology ·(unknown), Andrea Baran, Frank Passero, (unknown), Brea Lipe	0
7	P-292 Ongoing phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed/refractory multiple myeloma (MM) 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Sumit Madan, (unknown), Brea Lipe, Eva Medvedova, Andrew J. Cowan, (unknown), Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, (unknown), Salomon Manier, Yifah Yaron, Patrick P. Ng, Al‐Ola Abdallah	1
8	Onychomadesis and palmoplantar keratoderma associated with talquetamab therapy for relapsed and refractory multiple myeloma 2022 ·JAAD Case Reports ·(unknown), Benjamin F. Williams, Brea Lipe, Anna De Benedetto	8
9	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial 2020 ·The Lancet Haematology ·Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, (unknown), Jason Valent, Michael Rosenzweig, Jeffrey A. Zonder, Madhav V. Dhodapkar, Natalie S. Callander, Todd M. Zimmerman, Peter M. Voorhees, Brian G.M. Durie, S. Vincent Rajkumar, Paul G. Richardson, Robert Z. Orlowski	80
10	A review of thrombotic microangiopathies in multiple myeloma 2019 ·Leukemia Research ·Andrew J. Portuguese, (unknown), Frank Passero, Brea Lipe	18
11	A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics 2018 ·Leukemia Research ·Dandan Li, Tara L. Lin, Brea Lipe, Richard A. Hopkins, Heather Shinogle, Omar S. Aljitawi	16
12	Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma 2018 ·Clinical Lymphoma Myeloma & Leukemia ·Caroline M. Hsu, John M. Bennett, Brea Lipe	3
13	A Phase Ib/II Trial of Selinexor Combined with Lenalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma 2017 ·Blood ·Darrell White, Nizar J. Bahlis, Christopher P. Venner, Gary J. Schiller, Cristina Gasparetto, Heather J. Sutherland, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, William Bensinger, Brea Lipe, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Richard LeBlanc	4
14	Selinexor in Combination with Weekly Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate with Durable Responses in Patients with Refractory Multiple Myeloma (MM) 2017 ·Blood ·Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Suzanne Lentzsch, Rami Kotb, Christopher P. Venner, Cristina Gasparetto, Gary J. Schiller, Richard LeBlanc, William Bensinger, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Christine I. Chen	0
15	A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs) 2017 ·Blood ·Cristina Gasparetto, Suzanne Lentzsch, Gary J. Schiller, William Bensinger, Nizar J. Bahlis, Heather J. Sutherland, Darrell White, Michaël Sébag, Rami Kotb, Christopher P. Venner, Richard LeBlanc, Christine I. Chen, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Brea Lipe	2
16	Selinexor in Combination with Pomalidomide and Low Dose Dexamethasone in a Relapsed / Refractory Multiple Myeloma Patient Population with Prior Proteasome Inhibitor and Lenalidomide Exposure 2017 ·Blood ·Christine I. Chen, Heather J. Sutherland, Rami Kotb, Michaël Sébag, Darrell White, William Bensinger, Cristina Gasparetto, Richard LeBlanc, Christopher P. Venner, Suzanne Lentzsch, Gary J. Schiller, Brea Lipe, Aldo Del Col, Michael Kauffman, Sharon Shacham, Jacqueline Jeha, Jean‐Richard Saint‐Martin, Jatin J. Shah, Nizar J. Bahlis	3
17	Combined deficiency of factor V and factor VIII 2016 ·Blood Coagulation & Fibrinolysis ·(unknown), Brea Lipe	6
18	The role of maintenance therapy in multiple myeloma 2016 ·Blood Cancer Journal ·Brea Lipe, Rachel Vukas, Joseph Mıkhael	23
19	Bone marrow transplant for multiple myeloma: impact of distance from the transplant center. 2012 ·PubMed ·Brea Lipe, Frederick Lansigan, Jiang Gui, Kenneth R. Meehan	6
20	Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation 2011 ·Molecular Cancer Therapeutics ·Nancy B. Kuemmerle, Evelien Rysman, Portia S. Lombardo, (unknown), Brea Lipe, Wendy A. Wells, Jason R. Pettus, Heather M. Froehlich, Vincent A. Memoli, Peter M. Morganelli, Johannes V. Swinnen, Luika Timmerman, Leila Chaychi, (unknown), Burton Eisenberg, William B. Coleman, William B. Kinlaw	216

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact